Longboard Pharmaceuticals Inc has a consensus price target of $44 based on the ratings of 10 analysts. The high is $80 issued by Evercore ISI Group on July 2, 2024. The low is $16 issued by Cantor Fitzgerald on August 22, 2023. The 3 most-recent analyst ratings were released by Baird, Citigroup, and Evercore ISI Group on July 11, 2024, July 2, 2024, and July 2, 2024, respectively. With an average price target of $61.67 between Baird, Citigroup, and Evercore ISI Group, there's an implied 71.53% upside for Longboard Pharmaceuticals Inc from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
07/11/2024 | Buy Now | 66.9% | Baird | Joel Beatty | $36 → $60 | Maintains | Outperform | Get Alert |
07/02/2024 | Buy Now | 25.17% | Citigroup | David Hoang | $40 → $45 | Maintains | Buy | Get Alert |
07/02/2024 | Buy Now | 122.53% | Evercore ISI Group | Josh Schimmer | $57 → $80 | Maintains | Outperform | Get Alert |
06/20/2024 | Buy Now | 58.55% | Evercore ISI Group | Josh Schimmer | $44 → $57 | Maintains | Outperform | Get Alert |
06/20/2024 | Buy Now | 66.9% | Cantor Fitzgerald | Josh Schimmer | $60 → $60 | Reiterates | Overweight → Overweight | Get Alert |
06/11/2024 | Buy Now | 0.14% | B. Riley Securities | Kalpit Patel | $30 → $36 | Maintains | Buy | Get Alert |
06/11/2024 | Buy Now | 66.9% | HC Wainwright & Co. | Patrick Trucchio | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
05/07/2024 | Buy Now | 66.9% | HC Wainwright & Co. | Patrick Trucchio | → $60 | Reiterates | Buy → Buy | Get Alert |
05/03/2024 | Buy Now | 66.9% | Cantor Fitzgerald | Josh Schimmer | → $60 | Reiterates | Overweight → Overweight | Get Alert |
05/03/2024 | Buy Now | -5.42% | Wedbush | Laura Chico | $32 → $34 | Maintains | Outperform | Get Alert |
05/01/2024 | Buy Now | 0.14% | Baird | Joel Beatty | → $36 | Initiates | → Outperform | Get Alert |
04/16/2024 | Buy Now | 66.9% | HC Wainwright & Co. | Patrick Trucchio | → $60 | Reiterates | Buy → Buy | Get Alert |
04/10/2024 | Buy Now | 66.9% | Cantor Fitzgerald | Josh Schimmer | → $60 | Reiterates | Overweight → Overweight | Get Alert |
03/15/2024 | Buy Now | 66.9% | HC Wainwright & Co. | Patrick Trucchio | $60 → $60 | Maintains | Buy | Get Alert |
03/13/2024 | Buy Now | -10.99% | Wedbush | Laura Chico | → $32 | Reiterates | Outperform → Outperform | Get Alert |
03/13/2024 | Buy Now | 66.9% | Cantor Fitzgerald | Josh Schimmer | → $60 | Reiterates | Overweight → Overweight | Get Alert |
02/16/2024 | Buy Now | 11.27% | Citigroup | David Hoang | → $40 | Initiates | → Buy | Get Alert |
01/16/2024 | Buy Now | 66.9% | Cantor Fitzgerald | Josh Schimmer | $55 → $60 | Maintains | Overweight | Get Alert |
01/08/2024 | Buy Now | 66.9% | HC Wainwright & Co. | Patrick Trucchio | $25 → $60 | Maintains | Buy | Get Alert |
01/02/2024 | Buy Now | -10.99% | Guggenheim | Yatin Suneja | $16 → $32 | Maintains | Buy | Get Alert |
01/02/2024 | Buy Now | 52.99% | Cantor Fitzgerald | Josh Schimmer | $35 → $55 | Maintains | Overweight | Get Alert |
12/20/2023 | Buy Now | -2.64% | Cantor Fitzgerald | Josh Schimmer | → $35 | Reiterates | Overweight → Overweight | Get Alert |
12/19/2023 | Buy Now | -2.64% | Cantor Fitzgerald | Josh Schimmer | → $35 | Reiterates | Overweight → Overweight | Get Alert |
10/24/2023 | Buy Now | -2.64% | Cantor Fitzgerald | Josh Schimmer | $16 → $35 | Assumes | → Overweight | Get Alert |
10/12/2023 | Buy Now | -69.4% | Wedbush | Laura Chico | → $11 | Reiterates | Outperform → Outperform | Get Alert |
08/22/2023 | Buy Now | -55.49% | Cantor Fitzgerald | Alethia Young | → $16 | Reiterates | Overweight → Overweight | Get Alert |
08/07/2023 | Buy Now | -30.46% | HC Wainwright & Co. | Patrick Trucchio | → $25 | Reiterates | Buy → Buy | Get Alert |
07/11/2023 | Buy Now | -30.46% | HC Wainwright & Co. | Patrick Trucchio | → $25 | Reiterates | Buy → Buy | Get Alert |
07/06/2023 | Buy Now | -55.49% | Cantor Fitzgerald | Alethia Young | → $16 | Reiterates | Overweight → Overweight | Get Alert |
06/27/2023 | Buy Now | -55.49% | Cantor Fitzgerald | Alethia Young | → $16 | Reiterates | Overweight → Overweight | Get Alert |
05/12/2023 | Buy Now | -30.46% | HC Wainwright & Co. | Patrick Trucchio | → $25 | Reiterates | Buy → Buy | Get Alert |
05/11/2023 | Buy Now | -55.49% | Cantor Fitzgerald | Alethia Young | $11 → $16 | Maintains | Overweight | Get Alert |
05/10/2023 | Buy Now | -69.4% | Wedbush | Laura Chico | → $11 | Reiterates | → Outperform | Get Alert |
04/27/2023 | Buy Now | -63.84% | B. Riley Securities | Kalpit Patel | → $13 | Initiates | → Buy | Get Alert |
03/15/2023 | Buy Now | -30.46% | HC Wainwright & Co. | Patrick Trucchio | → $25 | Reiterates | → Buy | Get Alert |
03/09/2023 | Buy Now | -52.71% | Citigroup | Neena Bitritto-Garg | $24 → $17 | Maintains | Buy | Get Alert |
03/06/2023 | Buy Now | -52.71% | Citigroup | Neena Bitritto-Garg | $24 → $17 | Maintains | Buy | Get Alert |
11/11/2022 | Buy Now | -55.49% | Guggenheim | Yatin Suneja | $18 → $16 | Maintains | Buy | Get Alert |
04/27/2022 | Buy Now | -30.46% | HC Wainwright & Co. | Patrick Trucchio | → $25 | Initiates | → Buy | Get Alert |
02/14/2022 | Buy Now | -61.06% | Wedbush | Laura Chico | → $14 | Initiates | → Outperform | Get Alert |
The latest price target for Longboard Pharmaceuticals (NASDAQ:LBPH) was reported by Baird on July 11, 2024. The analyst firm set a price target for $60.00 expecting LBPH to rise to within 12 months (a possible 66.90% upside). 27 analyst firms have reported ratings in the last year.
The latest analyst rating for Longboard Pharmaceuticals (NASDAQ:LBPH) was provided by Baird, and Longboard Pharmaceuticals maintained their outperform rating.
There is no last upgrade for Longboard Pharmaceuticals
There is no last downgrade for Longboard Pharmaceuticals.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Longboard Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Longboard Pharmaceuticals was filed on July 11, 2024 so you should expect the next rating to be made available sometime around July 11, 2025.
While ratings are subjective and will change, the latest Longboard Pharmaceuticals (LBPH) rating was a maintained with a price target of $36.00 to $60.00. The current price Longboard Pharmaceuticals (LBPH) is trading at is $35.95, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.